One notable difference between spleen and tumor tissues was that 9-ING-41 significantly elevated CD4+ and CD8+ T-cell infiltration into the tumor tissues in comparison with PBS control, whereas the therapy failed to elevate T-cell recruitment in the spleen tissues, suggesting that systemically administered 9-ING-41 may induce a more pronounced T-cell response in immunosuppressive tumor microenvironment. Here, CD4 is linked to neoplasm.